Analysis – Page 2 – Goldea Capital

Vemanti Group Issues Statement Regarding Ongoing Investigation Related to ONUS Pro Platform

Written by Customer Service on March 26, 2026. Posted in Public Companies.

Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) — Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) today issues this statement regarding the ongoing investigation in Vietnam related to the ONUS Pro cryptocurrency platform (the “Platform”). The Company today learned of the indictments of Nhan (“Eric”) Vuong, Chairman of the Company’s Board of Directors, and Chien Tran, a member of the Company’s Board of Directors, through the official announcement by Vietnam’s Ministry of Public Security (the “MPS”) and Vietnamese news media, simultaneously with the general public. Prior to today, the Company had received no official communication from any authorities, law enforcement, or regulatory agencies in any jurisdiction regarding this matter. The Company...

Itafos Announces Restricted Share Unit and Deferred Share Unit Grants

Written by Customer Service on March 26, 2026. Posted in Public Companies.

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that the Company has granted, in the aggregate, 477,535 restricted share units (“RSUs”) and 32,738 deferred share units (“DSUs”) to directors and officers of the Company. The RSUs and DSUs granted to directors are scheduled to vest on a one-third per annum basis over a three-year period. The RSUs granted to officers are based on a combination of time and performance with 50% of the RSUs vesting 1/3 on the anniversary of the grant date over a period of three years and 50% of the RSUs vesting on the third anniversary of the grant date subject to achievement of certain key performance indicators as established by the Company’s Board of Directors. Each vested RSU entitles the holder to receive one share of the Company’s common stock...

XORTX Announces Results of Annual and Special Meeting of Shareholders

Written by Customer Service on March 26, 2026. Posted in Public Companies.

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George...

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders

Written by Customer Service on March 26, 2026. Posted in Public Companies.

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders Amsterdam, March 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced the resolutions to be submitted for adoption at the Annual General Meeting of Shareholders (AGM) which will be held in Amsterdam, the Netherlands, on May 27, 2026. The resolutions, proposed by the Supervisory Board, are:The adoption of the Company’s statutory annual accounts for the year ended December 31, 2025, prepared in accordance with International Financial Reporting Standards (IFRS). The 2025 statutory annual accounts1 were filed with the Netherlands Authority for the Financial Markets (AFM) on March 26, 2026 and are posted on the Company’s website...

Datacentrex Announces Pricing of $20.17 Million Confidentially Marketed Public Offering at $2.00 per Share

Written by Customer Service on March 26, 2026. Posted in Public Companies.

SALT LAKE CITY, March 26, 2026 (GLOBE NEWSWIRE) — Datacentrex, Inc. (Nasdaq: DTCX) (“Datacentrex” or the “Company”), a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses, today announced the pricing of its confidentially marketed public offering (the “Offering”) of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, at a public offering price of $2.00 per share (inclusive of the pre-funded warrant exercise price). The Company expects to receive aggregate gross proceeds of $20.17 million from the Offering, before deducting placement agent fees and other related expenses. The Offering is expected to close on or about March 30,...

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN PRAIRIE, Minn., March 26, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading...

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Written by Customer Service on March 26, 2026. Posted in Public Companies.

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD :The 2025 annual financial report; The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial...

Firan Technology Group Corporation (“FTG”) Announces First Quarter 2026 Earnings Release and Conference Call Dates

Written by Customer Service on March 26, 2026. Posted in Public Companies.

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — Firan Technology Group Corporation (TSX: FTG) (OTCQX: FTGFF) (“FTG”) will release the first quarter 2026 financial results after the market closes on Wednesday, April 8, 2026. The Corporation will host a live conference call on Thursday, April 9, 2026, at 8:30am (Eastern Time) to discuss the first quarter of 2026 financial results. Anyone wishing to participate in the call should dial 289-514-5100 or 1-800-717-1738, Conference ID 33073, and identify that you are calling to participate in the FTG conference call. The Chairperson is Mr. Brad Bourne. A replay of the call will be available until May 11, 2026, and will be available on the FTG website at www.ftgcorp.com. The number to call for a rebroadcast is 289-819-1325 or 1-888-660-6264, Playback Passcode 33073. ABOUT FIRAN TECHNOLOGY GROUP...

Lassonde Industries Inc. announces its Q4 and fiscal 2025 results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

ROUGEMONT, Quebec, March 26, 2026 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) today announced its financial results for its fourth quarter and year ended December 31, 2025. Financial Highlights: Fourth quarters ended Years endedDec. 31,2025 Dec. 31,2024 ∆ Dec. 31,2025 Dec. 31,2024 ∆(in millions of dollars, unless otherwise indicated) $ $ $ $ $ $Sales 768.1 738.1 30.0 2,934.0 2,600.9 333.1 Gross profit 225.0 192.9 32.1 801.5 698.1 103.4 Operating profit 71.1 43.0 28.1 226.1 174.7 51.4 Profit 54.2 27.8 26.4 149.4 113.4 36.0 Attributable to: Corporation’s shareholders 54.0 27.1 26.9 149.7 114.1 35.6 Non-controlling interests 0.2 0.7 (0.5 ) (0.3 ) (0.7 ) 0.4 EPS (in $) 7.92 3.97 3.95 21.94 16.73 5.21 Weighted...

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 BOTHELL, Wash., March 26, 2026 (GLOBE NEWSWIRE) — LeonaBio,...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals